Chinese herbal medicines for hypercholesterolemia

被引:36
|
作者
Liu, Zhao Lan [1 ]
Liu, Jian Ping [1 ]
Zhang, Anthony Lin [2 ]
Wu, Qiong [3 ]
Ruan, Yao
Lewith, George
Visconte, Denise [4 ]
机构
[1] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing 100029, Peoples R China
[2] RMIT Univ, Sch Hlth Sci, Discipline Chinese Med, Bundoora, Vic, Australia
[3] Beijing Univ Chinese Med, Sch Humanities, Beijing 100029, Peoples R China
[4] Primary Med Care, Complementary & Integrated Med Res Unit, Southampton, Hants, England
来源
COCHRANE DATABASE OF SYSTEMATIC REVIEWS | 2011年 / 07期
关键词
DENSITY-LIPOPROTEIN CHOLESTEROL; SUGAR-CANE POLICOSANOL; CORONARY-HEART-DISEASE; PLASMA-CHOLESTEROL; RANDOMIZED-TRIALS; PLANT STEROLS; DOUBLE-BLIND; QUALITY; COMBINATION; EFFICACY;
D O I
10.1002/14651858.CD008305.pub2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Hypercholesterolemia is an important key contributory factor for ischemic heart disease and is associated with age, high blood pressure, a family history of hypercholesterolemia, and diabetes. Chinese herbal medicines have been used for a long time as lipid-lowering agents. Objectives To assess the effects of Chinese herbal medicines on hypercholesterolemia. Search strategy We searched the following databases: The Cochrane Library (issue 8, 2010), MEDLINE (until July 2010), EMBASE (until July 2010), Chinese BioMedical Database (until July 2010), Traditional Chinese Medical Literature Analysis and Retrieval System (until July 2010), China National Knowledge Infrastructure (until July 2010), Chinese VIP Information (until July 2010), Chinese Academic Conference Papers Database and Chinese Dissertation Database (until July 2010), and Allied and Complementary Medicine Database (until July 2010). Selection criteria We considered randomized controlled clinical trials in hypercholesterolemic participants comparing Chinese herbal medicines with placebo, no treatment, and pharmacological or non-pharmacological interventions. Data collection and analysis Two review authors independently extracted data and assessed the risk of bias. We resolved any disagreements with this assessment through discussion and a decision was achieved based by consensus. We assessed trials for the risk of bias against key criteria: random sequence generation, allocation concealment, blinding of participants, incomplete outcome data, selective outcome reporting and other sources of bias. Main results We included 22 randomized trials (2130 participants). The mean treatment duration was 2.3 +/- 1.3 months (ranging from one to six months). Twenty trials were conducted in China and 18 trials were published in Chinese. Overall, the risk of bias of included trials was high or unclear. Five different herbal medicines were evaluated in the included trials, which compared herbs with conventional medicine in six comparisons (20 trials), or placebo (two trials). There were no outcome data in any of the trials on cardiovascular events and death from any cause. One trial each reported well-being (no significant differences) and economic costs. No serious adverse events were observed. Xuezhikang was the most commonly used herbal formula investigated. A significant effect on total cholesterol (two trial, 254 participants) was shown in favor of Xuezhikang when compared with inositol nicotinate (mean difference (MD) -0.90 mmol/L, 95% confidence interval (CI) -1.13 to -0.68). Authors' conclusions Some herbal medicines may have cholesterol-lowering effects. Our findings have to be interpreted with caution due to high or unclear risk of bias of the included trials.
引用
收藏
页数:111
相关论文
共 50 条
  • [21] Herbal medicines in the treatment of tinnitus: An updated review
    Liu, Dongliang
    Hu, Yue
    Wang, Dali
    Han, Hezhou
    Wang, Yi
    Wang, Xilu
    Zhou, Zhaoyu
    Ma, Xiulan
    Dong, Yaodong
    FRONTIERS IN PHARMACOLOGY, 2023, 13
  • [22] An Overview of Herbal Medicines for Idiopathic Pulmonary Fibrosis
    Murthy, Pavitra
    Shaibie, Nur Adania
    Lim, Chooi Ling
    Ling, Anna Pick Kiong
    Chye, Soi Moi
    Koh, Rhun Yian
    PROCESSES, 2022, 10 (06)
  • [23] Phytotherapy and quality of herbal medicines
    Capasso, R
    Izzo, AA
    Pinto, L
    Bifulco, T
    Vitobello, C
    Mascolo, N
    FITOTERAPIA, 2000, 71 : S58 - S65
  • [24] Chinese herbal medicines for the treatment of depression: a systematic review and network meta-analysis
    Dang, Chun
    Wang, Qinxuan
    Li, Qian
    Xiong, Ying
    Lu, Yaoheng
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [25] Looking to the Future of Herbal Medicines
    Meier, Beat
    Knoess, Werner
    Wenng, Andreas
    Saller, Reinhard
    FORSCHENDE KOMPLEMENTARMEDIZIN, 2014, 21 : 29 - 34
  • [26] Herbal medicines for psychiatric disorders
    Anheyer, D.
    Haller, H.
    Klose, P.
    Cramer, H.
    Dobos, G.
    NERVENARZT, 2018, 89 (09): : 1009 - 1013
  • [27] Herbal medicines in migraine prevention
    DeWeerdt, CJ
    Bootsma, HPR
    Hendriks, H
    PHYTOMEDICINE, 1996, 3 (03) : 225 - 230
  • [28] RETRACTED: Herbal medicines for viral myocarditis (Retracted Article)
    Liu, Zhao Lan
    Liu, Zhi Jun
    Liu, Jian Ping
    Kwong, Joey S. W.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (11):
  • [29] The Efficacy and Mechanism of Chinese Herbal Medicines in Lowering Serum Uric Acid Levels: A Systematic Review
    Chen, Liqian
    Luo, Zhengmao
    Wang, Ming
    Cheng, Jingru
    Li, Fei
    Lu, Hanqi
    He, Qiuxing
    You, Yanting
    Zhou, Xinghong
    Kwan, Hiu Yee
    Zhao, Xiaoshan
    Zhou, Lin
    FRONTIERS IN PHARMACOLOGY, 2021, 11
  • [30] Pharmacovigilance: a step towards the rational use of herbs and herbal medicines
    Balbino, Evelin E.
    Dias, Murilo F.
    REVISTA BRASILEIRA DE FARMACOGNOSIA-BRAZILIAN JOURNAL OF PHARMACOGNOSY, 2010, 20 (06): : 992 - 1000